Clinical trial
Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy
NCT00127881 is registered in ClinicalTrials.gov with Emergent Product Development Seattle LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy
- Lead sponsor
- Emergent Product Development Seattle LLC
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- July 31, 2005
- Completion date
- Not reported
- Enrollment
- 76 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.